Dr. May, CEO of Canada’s Centre for Commercialization of Regenerative Medicine (CCRM), brings 20 years of sector knowledge, leadership experience, and extensive global industry and investor networks
ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that Michael H. May, Ph.D., has joined its Board of Directors. Dr. May fills a recent vacancy on the Board for an independent member, following the departure of Michael Mulroy, which was not because of a disagreement with AgeX on any matter relating to company operations, policies, or practices.
Dr. May is President and CEO of Canada’s Centre for Commercialization of Regenerative Medicine (CCRM), a leading and highly successful public-private partnership, which he has grown from inception to over 100 experts, and which under his leadership has raised over $100M, with spin-off companies and academic partners supported by CCRM securing an additional $750M. Dr. May has extensive experience serving on a diverse range of company boards and industry-focused advisory committees, including at the International Society for Cell Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), and the International Society for Stem Cell Research (ISSCR). Dr. May holds a Ph.D. in Chemical Engineering from the University of Toronto.
“We are pleased to welcome Dr. May to the Board of AgeX,” said Greg Bailey, M.D., Chairperson of the Board of Directors of AgeX. “Dr. May is a globally-recognized leader in regenerative medicine. We believe Dr. May will play an invaluable role in unlocking the commercial value of PureStem®, AgeX’s cell derivation and manufacturing platform, and UniverCyte™, AgeX’s cell immune tolerance platform, through global partnerships, while simultaneously helping to progress our internal cell therapy programs toward the clinic and commercialization.” Dr. Bailey added, “All of us at AgeX would like to thank Michael Mulroy for his invaluable service to AgeX during its formation and transition to a public company, and we wish him all the best in future endeavors.”
“AgeX has a number of transformative platform technologies across the entire regenerative medicine space,” said Dr. May. “I am delighted to be joining the Board at this exciting time, and I look forward to contributing to the success of the company.”